



# PD Dr. Martin Früh

## contact

<b>titel</b>	PD Dr.
<b>first name</b>	Martin
<b>last name</b>	Früh
<b>country</b>	Switzerland
<b>e-mail</b>	<a href="mailto:martin.frueh@kssg.ch">martin.frueh@kssg.ch</a>

## publications

### title

#### journal paper/ review

Baty F, Joerger M, Früh M, Klingbiel D, Zappa F, Brutsche M. 24h-gene variation effect of combined bevacizumab/erlotinib in advanced non-squamous non-small cell lung cancer using exon array blood profiling. *J Transl Med* 2017; 15:66.

Ess S M, Herrmann C, Frick H, Krapf M, Cerny T, Jochum W, Früh M. Epidermal growth factor receptor and anaplastic lymphoma kinase testing and mutation prevalence in patients with advanced non-small cell lung cancer in Switzerland: A comprehensive evaluation of real world practices. *Eur J Cancer Care (Engl)* 2017;.

siano m, Molinari F, Martin V, Mach N, Früh M, Freguia S, Corradino I, Ghielmini M, Frattini M, Espeli V. Multicenter Phase II Study of Panitumumab in Platinum Pretreated, Advanced Head and Neck Squamous Cell Cancer. *Oncologist* 2017;.

Delaunay M, Cadranel J, Lusque A, Meyer N, Gouyant V, Moro-Sibilot D, Michot J M, Raimbourg J, Girard N, Guisier F, Planchard D, Metivier A C, Tomasini P, Dansin E, Pérol M, Campana M, Gautschi O, Früh M, Fumet J D, Audigier-Valette C, Couraud S, Dalle S, Leccia M T, Jaffro M, Collot S, Prévot G, Milia J, Mazières J. Immune-checkpoint inhibitors associated with interstitial lung disease in cancer patients. *Eur Respir J* 2017; 50:.

Diem S, Schmid S, Krapf M, Flatz L, Born D, Jochum W, Templeton A J, Früh M. Neutrophil-to-Lymphocyte ratio (NLR) and Platelet-to-Lymphocyte ratio (PLR) as prognostic markers in patients with non-small cell lung cancer (NSCLC) treated with nivolumab. *Lung Cancer* 2017; 111:176-181.

## publications

### title

#### journal paper/ review

---

Glatzer M, Rittmeyer A, Müller J, Opitz I, Früh M, Papachristofilou A, Psallidas I, Born D, Putora P M. Treatment of limited disease small cell lung cancer: the multidisciplinary team. European Respiratory Journal 2017;.

---

Gautschi O, Milia J, Filleron T, Wolf J, Carbone D P, Owen D, Camidge R, Narayanan V, Doebele R C, Besse B, Remon-Masip J, Jänne P A, Awad M M, Peled N, Byoung C C, Karp D D, Van Den Heuvel M, Wakelee H A, Neal J W, Mok T S K, Yang J C H, Ou S H I, Pall G, Froesch P, Zalcman G, Gandara D R, Riess J W, Velcheti V, Zeidler K, Diebold J, Früh M, Michels S, Monnet I, Popat S, Rosell R, Karachaliou N, Rothschild S I, Shih J Y, Warth A, Muley T, Cabillic F, Mazières J, Drilon A. Targeting RET in Patients With RET-Rearranged Lung Cancers: Results From the Global, Multicenter RET Registry. J Clin Oncol 2017; 35:1403-1410.

---

Glatzer M, Rittmeyer A, Müller J, Opitz I, Papachristofilou A, Psallidas I, Früh M, Born D, Putora P M. Treatment of limited disease small cell lung cancer: the multidisciplinary team. Eur Respir J 2017; 50:.

---

Parra-Guillen Z P, Berger P B, Haschke M, Donzelli M, Winogradova D, Pfister B, Früh M, Gillissen Sommer S, Krähenbühl S, Kloft C, Joerger M. Role of Cytochrome P450 3A4 and 1A2 Phenotyping in Patients with Advanced Non-small-Cell Lung Cancer Receiving Erlotinib Treatment. Basic Clin Pharmacol Toxicol 2017; 121:309-315.

## publications

### title

#### journal paper/ review

Rosell R, Dafni U, Felip E, Curioni-Fontecedro A, Gautschi O, Peters S, Massutí B, Palmero R, Aix S P, Carcereny E, Früh M, Pless M, Popat S, Kotsakis A, Cuffe S, Bidoli P, Favaretto A, Froesch P, Reguart N, Puente J, Coate L, Barlesi F, Rauch D, Thomas M, Camps C, Gómez-Codina J, Majem M, Porta R, Shah R, Hanrahan E, Kammler R, Ruepp B, Rabaglio M, Kassapian M, Karachaliou N, Tam R, Shames D S, Molina-Vila M A, Stahel R A, BELIEF collaborative group . Erlotinib and bevacizumab in patients with advanced non-small-cell lung cancer and activating EGFR mutations (BELIEF): an international, multicentre, single-arm, phase 2 trial. *Lancet Respir Med* 2017; 5:435-444.

Peters S, Gettinger S, Johnson M L, Jänne P A, Garassino M C, Christoph D, Toh C K, Rizvi N A, Chaft J E, Carcereny Costa E, Patel J D, Chow L Q M, Koczywas M, Ho C, Früh M, van den Heuvel M, Rothenstein J, Reck M, Paz-Ares L, Shepherd F A, Kurata T, Li Z, Qiu J, Kowanetz M, Mocchi S, Shankar G, Sandler A, Felip E. Phase II Trial of Atezolizumab As First-Line or Subsequent Therapy for Patients With Programmed Death-Ligand 1-Selected Advanced Non-Small-Cell Lung Cancer (BIRCH). *J Clin Oncol* 2017; 35:2781-2789.

Hasan Ali O, Diem S, Markert E, Jochum W, Kerl K, French L E, Speiser D E, Früh M, Flatz L. Characterization of nivolumab-associated skin reactions in patients with metastatic non-small cell lung cancer. *Oncoimmunology* 2016; 5:e1231292.

Baty F, Joerger M, Früh M, Brutsche M. 61PD 24h-blood profile gene expression biomarkers of the response to targeted therapy in advanced non-squamous non-small cell lung cancer (NSCLC). *J Thorac Oncol* 2016; 11:S81.

Putora P M, Szentesi K, Glatzer M, Rodriguez R, Müller J, Baty F, Früh M. SUVmax and Tumour Location in PET-CT Predict Oncogene Status in Lung Cancer. *Oncol Res Treat* 2016; 39:681-686.

## publications

### title

#### journal paper/ review

Früh M, Ris H B, Xyrafas A, Peters S, Mirimanoff R O, Gautschi O, Pless M, Stupp R. Preoperative chemoradiotherapy with cisplatin and docetaxel for stage IIIB non-small-cell lung cancer: 10-year follow-up of the SAKK 16/01 trial. *Ann Oncol* 2016; 27:1971-3.

Gautschi O, Rothschild S I, Li Q, Matter-Walstra K, Zippelius A, Betticher D C, Früh M, Stahel R A, Cathomas R, Rauch D, Pless M, Peters S, Froesch P, Zander T, Schneider M, Biaggi C, Mach N, Ochsenbein A F, . Bevacizumab Plus Pemetrexed Versus Pemetrexed Alone as Maintenance Therapy for Patients With Advanced Nonsquamous Non-Small-cell Lung Cancer: Update From the Swiss Group for Clinical Cancer Research (SAKK) 19/09 Trial. *Clin Lung Cancer* 2016;.

Schmid S, Gautschi O, Rothschild S, Mark M, Froesch P, Klingbiel D, Reichegger H, Jochum W, Diebold J, Früh M. Clinical Outcome of ALK-Positive Non-Small Cell Lung Cancer (NSCLC) Patients with De Novo EGFR or KRAS Co-Mutations Receiving Tyrosine Kinase Inhibitors (TKIs). *J Thorac Oncol* 2016;.

Bickel A, Koneth I,ENZLER-Tschudy A, Neuweiler J, Flatz L, Früh M. Pembrolizumab-associated minimal change disease in a patient with malignant pleural mesothelioma. *BMC Cancer* 2016; 16:656.

Reichegger H, Jochum W, Förbs D, Hader C, Früh M. Rapid Intracranial Response to Osimertinib in a Patient with Epidermal Growth Factor Receptor T790M-Positive Adenocarcinoma of the Lung. *Oncol Res Treat* 2016; 39:461-3.

Neumair P, Joos L, Warschkow R, Dutly A, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, cerny t, Joerger M. Erlotinib has comparable clinical efficacy to chemotherapy in pretreated patients with advanced non-small cell lung cancer (NSCLC): A propensity-adjusted, outcomes research-based study. *Lung Cancer* 2016; 100:38-44.

## publications

### title

#### journal paper/ review

Gautschi O, Mach N, Rothschild S I, Li Q, Stahel R A, Zippelius A, Cathomas R, Früh M, Betticher D C, Peters S, Rauch D, Feilchenfeldt J, Bubendorf L, Savic S, Jaggi R, Leibundgut E O, Largiadèr C, Brutsche M, Pilop C, Stalder L, Pless M, Ochsenbein A F, Swiss Group for Clinical Cancer Research . Bevacizumab, Pemetrexed, and Cisplatin, or Bevacizumab and Erlotinib for Patients With Advanced Non-Small-Cell Lung Cancer Stratified by Epidermal Growth Factor Receptor Mutation: Phase II Trial SAKK19/09. Clin Lung Cancer 2015; 16:358-65.

Putora P M, Ess S, Panje C, Hundsberger T, van Leyen K, Plasswilm L, Früh M. Prognostic significance of histology after resection of brain metastases and whole brain radiotherapy in non-small cell lung cancer (NSCLC). Clin Exp Metastasis 2015; 32:143-9.

Stahel R A, Riesterer O, Xyrafas A, Opitz I, Beyeler M, Ochsenbein A, Früh M, Cathomas R, Nackaerts K, Peters S, Mamot C, Zippelius A, Mordasini C, Caspar C B, Eckhardt K, Schmid R A, Aebersold D M, Gautschi O, Nagel W, Töpfer M, Krayenbuehl J, Ribi K, Ciernik L F, Weder W. Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma with or without hemithoracic radiotherapy (SAKK 17/04): a randomised, international, multicentre phase 2 trial. Lancet Oncol 2015; 16:1651-8.

Mazières J, Barlesi F, Filleron T, Besse B, Monnet I, Beau-Faller M, Peters S, Dansin E, Früh M, Pless M, Rosell R, Wislez M, Fournel P, Westeel V, Cappuzzo F, Cortot A, Moro-Sibilot D, Milia J, Gautschi O. Lung cancer patients with HER2 mutations treated with chemotherapy and HER2-targeted drugs: results from the European EUHER2 cohort. Ann Oncol 2015; 27:281-6.

## publications

### title

#### journal paper/ review

Gautschi O, Milia J, Cabarrou B, Bluthgen M V, Besse B, Smit E F, Wolf J, Peters S, Früh M, Koeberle D, Oulkhovir Y, Schuler M, Curioni-Fontecedro A, Huret B, Kerjouan M, Michels S, Pall G, Rothschild S, Schmid-Bindert G, Scheffler M, Veillon R, Wannesson L, Diebold J, Zalcman G, Filleron T, Mazières J. Targeted Therapy for Patients with BRAF-Mutant Lung Cancer: Results from the European EURAF Cohort. *J Thorac Oncol* 2015; 10:1451-7.

Koeberle D, Betticher D C, von Moos R, Dietrich D, Brauchli P, Baertschi D, Matter K, Winterhalder R, Borner M, Anchisi S, Moosmann P, Kollar A, Saletti P, Roth A, Früh M, Kueng M, Popescu R A, Schacher S, Hess V, Herrmann R. Bevacizumab continuation versus no continuation after first-line chemotherapy plus bevacizumab in patients with metastatic colorectal cancer: a randomized phase III non-inferiority trial (SAKK 41/06). *Ann Oncol* 2015; 26:709-14.

Pless M, Stupp R, Ris H B, Stahel R A, Weder W, Thierstein S, Gerard M A, Xyrafas A, Früh M, Cathomas R, Zippelius A, Roth A, Bijelovic M, Ochsenbein A, Meier U R, Mamot C, Rauch D, Gautschi O, Betticher D C, Mirimanoff R O, Peters S, . Induction chemoradiation in stage IIIA/N2 non-small-cell lung cancer: a phase 3 randomised trial. *Lancet* 2015; 386:1049-56.

Diem S, Ess S, cerny t, Früh M, Hitz F. Diffuse large B-cell lymphoma in elderly patients: a retrospective analysis. *Eur J Intern Med* 2014; 25:577-82.

Sebastian M, Papachristofilou A, Weiss C, Früh M, Cathomas R, Hilbe W, Wehler T, Rippin G, Koch S D, Scheel B, Fotin-Mleczek M, Heidenreich R, Kallen K J, Gnad-Vogt U, Zippelius A. Phase Ib study evaluating a self-adjuvanted mRNA cancer vaccine (RNActive®) combined with local radiation as consolidation and maintenance treatment for patients with stage IV non-small cell lung cancer. *BMC Cancer* 2014; 14:748.

## publications

### title

#### journal paper/ review

Leitner C, Von Moos R, Früh M, Mark M, Cathomas R. Progressive brain metastases in an EGFR mutated adenocarcinoma of the lung: Response to gefitinib after progression on erlotinib. *Cancer Treatment Communications* 2014; 2:4-7.

Joerger M, Baty F, Früh M, Droege C, Stahel R A, Betticher D C, von Moos R, Ochsenbein A, Pless M, Gautschi O, Rothschild S, Brauchli P, Klingbiel D, Zappa F, Brutsche M. Circulating microRNA profiling in patients with advanced non-squamous NSCLC receiving bevacizumab/erlotinib followed by platinum-based chemotherapy at progression (SAKK 19/05). *Lung Cancer* 2014; 85:306-13.

Diem S, Früh M, Rodriguez R, Liechti P, Rothermundt C. EML4-ALK-Positive Pulmonary Adenocarcinoma with an Unusual Metastatic Pattern: A Case Report. *Case Rep Oncol* 2013; 6:316-9.

Schwitler M, Früh M, Schneider T, Kluckert J T, Rodriguez R, Brutsche M. Epidermal Growth Factor Receptor Mutation in a Patient with Squamous Cell Carcinoma of the Lung: Who Should Be Tested?. *Oncology* 2013; 2013:263-268.

Früh M, Besrouer H, Gillessen Sommer S, Joerger M, Hitz F, Savidan A, cerny t, Ess S. Management of elderly patients with advanced non-small cell lung cancer: a single-center experience. *Chemotherapy* 2013; 59:42-50.

Putora P M, Früh M, Müller J. FDG-PET SUV-max values do not correlate with epidermal growth factor receptor mutation status in lung adenocarcinoma. *Respirology* 2013; 18:734-5.

Schwitler M, Rodriguez R, Schneider T, Kluckert T, Brutsche M, Früh M. Epidermal growth factor receptor mutation in a patient with squamous cell carcinoma of the lung: who should be tested?. *Case Rep Oncol* 2013; 6:263-8.



## publications

### title

#### journal paper/ review

Baty F, Rothschild S, Früh M, Betticher D, Dröge C, Cathomas R, Rauch D, Gautschi O, Bubendorf L, Crowe S, Zappa F, Pless M, Brutsche M, Swiss Group for Clinical Cancer Research . EGFR Exon-Level Biomarkers of the Response to Bevacizumab/Erlotinib in Non-Small Cell Lung Cancer. PLoS ONE 2013; 8:e72966.

hochstrasser a, Benz G, Joerger M, templeton a, Brutsche M, Früh M. Interstitial Pneumonitis after Treatment with Pemetrexed: A Rare Event?. Chemotherapy 2012; 58:84-88.

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.

Putora P M, Schneider T, Rodriguez R, Früh M. Targeted therapy in non-small cell lung cancer. Breathe 2012; 8:206-215.

Joerger M, Matter-Walstra K, Früh M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. Ann Oncol 2012; 22:567-574.

Früh M, Cathomas R, siano m, Tscherry G, Zippelius A, Mamot C, Erdmann A, Krasniqi F, Rauch D, Simcock M, Küttel E, Fustier P, Pless M, Swiss Group for Clinical Cancer Research . Carboplatin and paclitaxel plus ASA404 as first-line chemotherapy for extensive-stage small-cell lung cancer: a multicenter single arm phase II trial (SAKK 15/08). Clin Lung Cancer 2012; 14:34-9.

Rossi A, Di Maio M, Chiodini P, Rudd R, Okamoto H, Skarlos D, Früh M, Qian W, Tamura T, Samantas E, Shibata T, Perrone F, Gallo C, Gridelli C, Martelli O, Lee S. Carboplatin- or Cisplatin-based chemotherapy in first-line treatment of small cell lung cancer: The COCIS individual patient data meta-analysis. J Clin Oncol 2012;1692-1698.

## publications

### title

#### journal paper/ review

Stahel R, Thatcher N, Früh M, Le Péchoux C, Postmus P E, Sorensen J B, Felix E, Panel members . 1st ESMO Consensus Conference in lung cancer; Lugano 2010: small-cell lung cancer. Ann Oncol. 2011; 22:1973-1980.

Früh M. The search for improved systemic therapy of non-small cell lung cancer--what are today's options?. Lung Cancer 2011; 72:265-270.

Putora P M, Früh M. The place of radiotherapy in the palliative management of NSCLC. Breathe 2011; 8: 134-143 2011;.

Früh M, Kacsir B, Ess S, cerny t, Rodriguez R, Plasswilm L. Extrapulmonary small cell carcinoma: An indication for prophylactic cranial irradiation? A single center experience. Strahlenther Onkol 2011; 187:561-7.

Putora P M, Benz G, Rodriguez R, Brutsche M, Früh M. Tracheal granuloma pyogenicum with erlotinib treatment for lung cancer. Eur Respir J 2011; 38:1228-30.

bastian s, Clerici T, Neuweiler J, cerny t, Früh M. Surgical resection of isolated adrenal metastases in patients with non-small cell lung cancer: a single-institution experience and review of the literature. Onkologie 2011; 34:665-70.

Joerger M, Omlin A, cerny t, Früh M. The role of pemetrexed in advanced non small-cell lung cancer: special focus on pharmacology and mechanism of action. Current drug targets 2010; 11:37-47.

Früh M, Shepherd F. Adjuvant Cisplatin-Based Chemotherapy for Elderly. EUROPEAN JOURNAL OF CLINICAL & MEDICAL ONCOLOGY 2010;59-63.

## publications

### title

#### journal paper/ review

Joerger M, Matter-Walstra K, Früh M, Kühnel U, Szucs T, Pestalozzi B, Schwenkglenks M. Addition of cetuximab to first-line chemotherapy in patients with advanced non-small-cell lung cancer: a cost-utility analysis. *Ann Oncol* 2010; 22:567-74.

D'Addario G, Früh M, Reck M, Baumann P, Klepetko W, Felip E, ESMO Guidelines Working Group . Metastatic non-small-cell lung cancer: ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up. *Ann Oncol* 2010; 21 Suppl 5:v116-9.

Cerny D, cerny t, ess s, D'Addario G, Früh M. Lung Cancer in the Canton of St. Gallen, Eastern Switzerland:. *Onkologie* 2009; 32:569-73.

Früh M, Pignon J P, Shepherd F. Review Article: Elderly patients with early non-small cell lung cancer: What are the benefits and harms of adjuvant platinum-based chemotherapy?. *AJHO* 2009; 8:76-79.

Omlin A, D'Addario G, Gillessen Sommer S, cerny t, vonhessling a, Früh M. Activity of pemetrexed against brain metastases in a patient with adenocarcinoma of the lung. *Lung cancer (Amsterdam, Netherlands)* 2009; 65:383-4.

Früh M, Zhou W, Zhai R, Su L, Heist R S, Wain J C, Nishioka N S, Lynch T J, Shepherd F A, Christiani D C, Liu G. Polymorphisms of inflammatory and metalloproteinase genes, *Helicobacter pylori* infection and the risk of oesophageal adenocarcinoma. *British journal of cancer* 2008; 98:689-92.

Früh M, Rolland E, Pignon J P, Seymour L, Ding K, Tribodet H, Winton T, Le Chevalier T, Scagliotti G V, Douillard J Y, Spiro S, Shepherd F A. Pooled analysis of the effect of age on adjuvant cisplatin-based chemotherapy for completely resected non-small-cell lung cancer. *Journal of clinical oncology : official journal of the American Society of Clinical Oncology* 2008; 26:3573-81.

## publications

### title

#### journal paper/ review

Früh M, Gillessen Sommer S, cerny t, Demmer-Steingruber R, D'Addario G. Two-weekly gemcitabine fixed dose rate and oxaliplatin combination chemotherapy for advanced non-small-cell lung cancer. Lung cancer (Amsterdam, Netherlands) 2008; 62:344-50.

Rodin G, Zimmermann C, Rydall A, Jones J, Shepherd F A, Moore M, Früh M, Donner A, Gagliese L. The desire for hastened death in patients with metastatic cancer. Journal of pain and symptom management 2007; 33:661-75.

Lanz C, Früh M, Thormann W, cerny t, Lauterburg B H. Rapid determination of gemcitabine in plasma and serum using reversed-phase HPLC. Journal of separation science 2007; 30:1811-20.

Früh M, Ruhstaller T, Neuweiler J, cerny t. Resection of skin metastases from gastric carcinoma with long-term follow-up: an unusual clinical presentation. Onkologie 2005; 28:38-40.

Früh M. Use of second-line biochemical and susceptibility tests for the differential identification of coryneform bacteria. Clinical Microbiology and Infection 1998; Vol. 4 June 1998:.

#### book chapter

Früh M (2014). Advances in Radiotherapy for Locally Advanced NSCLC. In New Therapeutic Strategies in Lung Cancers (pp. 69-94): Springer.

Früh M (2014). Strategy on Patients with EGFR Mutation. In New Therapeutic Strategies in Lung Cancers (pp. 133-145): Springer.

Früh M, Baty F, Putora P M, & Brutsche M (2011). Advances in Personalized Cancer Management. In Advances in Personalized Cancer Management (pp. 58-67). London: Future Medicine Ltd.

## publications

### title

---

**conference  
paper/  
poster**

Neumair P, Joos L, Warschkow R, Ess S, Hitz F, Früh M, Brutsche M, Baty F, Krähenbühl S, & Joerger M (2016). Chemotherapy is not superior to erlotinib in pretreated patients with advanced non-small cell lung cancer (NSCLC): A retrospective study: Abstrakt 169P. In J Thorac Oncol. 11(4 Suppl) (pp. 131): Elsevier.

---

Klass N, Klaeser B, toepfer m, Malthaner M, Früh M, Schmidhalter D, Cihoric N, Born E, Blumstein N, Plasswilm L, Krause T, Aebersold D, & Schmuecking M (2012). Non-Gated F-18 FDG PET/CT For Target Volume Delineation in Stereotactic Body Radiation Therapy (SBRT) in Patients with Malignant Lung Lesions and Clinical Outcome. In (pp. 106): SASRO.



## projects

**title**

**status**

---

Effect of induction chemotherapy on lung function measured by scheduled spiroergometry and 6-Minute walking test in patients affected by non-small cell lung cancer (NSCLC)



## projects

<b>title</b>	<b>status</b>
Randomisierte, doppelblinde, placebokontrollierte Phase III-Studie zu Rovalpituzumab Tesirin als Erhaltungstherapie nach einer Erstlinienchemotherapie auf Platin-basis bei Studienteilnehmern mit ausgebreitetem (extensive-stage) kleinzelligem Bronchialkarzinom (MERU)	ongoing - recruiting phase
SAKK 17/16: Lurbinectedin Monotherapy in Patients with Progressive Malignant Pleural Mesothelioma. A Multicenter, Single-arm Phase II Trial	ongoing - recruiting phase

## projects

title	status
ETOP 10-16 BOOSTER: A randomised phase II trial of osimertinib and bevacizumab versus osimertinib alone as second-line treatment in stage IIIb-IVb NSCLC with con-firmed EGFRm and T790M	ongoing - recruiting phase





## projects

title	status
SAKK 19/16: Binimetinib, pemetrexed and cisplatin, followed by maintenance with binimetinib and pemetrexed, in patients with advanced non-small cell lung cancer with KRAS mutationsA multicenter phase IB trial	ongoing - recruiting phase



## projects

<b>title</b>	<b>status</b>
CA209451: Randomized, Multicenter, Double-Blind, Phase 3 Study of Nivolumab, Nivolumab in Combination with Ipilimumab, or Placebo as Maintenance Therapy in Subjects with Extensive-Stage Disease Small Cell Lung Cancer (ED-SCLC) after Completion of Platinum-based First Line Chemotherapy. CheckMate 451	ongoing - follow up



## projects

<b>title</b>	<b>status</b>
A phase III, open-label, randomized study of MPDL3280A (Anti PD-L1 antibody) in combination with carboplatin Paclitaxel with or without bevacizumab compared with carboplatin Paclitaxel bevacizumab in chemotherapy naïve patients with stage IV non-squamous non-small cell lung cancer	ongoing - follow up

## projects

title	status
A randomized, phase 3 trial with anti-PD-1 monoclonal antibody pembrolizumab (MK-3475) versus placebo for patients with early stage NSCLC after resection and completion of standard adjuvant therapy (PEARLS)	ongoing - follow up
An open-label, multicohort, phase II study of MPDL3280A in advanced solid tumors	ongoing - follow up
Predictive and prognostic value of integrated exon-level expression to approach drug-response and resistance to EGFR-targeted treatment in non-small cell lung cancer	automat- ically closed
Patient-centred personalised palliative cancer care: A pilot feasibility study of patient-derived clinical benefit-guided chemotherapy in advanced non-small cell lung cancer (NSCLC) patients with a performance status (PS) of 2-3 due to lung cancer (Phönix)	completed

## projects

title	status
A phase III, multicenter, randomized, open-label study of oral LDK378 versus standard chemotherapy in adult patients with ALK-rearranged (ALK-positive) advanced non-small cell lung cancer who have been treated previously with chemotherapy (platinum doublet) and crizotinib	automatically closed

## projects

title	status
Circulating micro-RNA profiling in patients with advanced non-squamous non small-cell lung cancer receiving bevacizumab/erlotinib first-line treatment followed by platinum-based chemotherapy at disease progression (SAKK 19/05)	completed
Cytochrom p450 3A4 and 1A2 phenotyping for the individualization of treatment with sunitinib or erlotinib in cancer patients	automatically closed
ETOP 2-11 (BELIEF) An open-label phase II trial of erlotinib and bevacizumab in patients with advanced non-small cell lung cancer and activating EGFR mutations	ongoing - follow up
A randomized double blind phase 3 efficacy and safety study of PF-00299804 versus erlotinib for the treatment of advanced non-small cell lung cancer following progression after, or intolerance to, at least one prior chemotherapy	automatically closed
Phase II study to investigate the efficacy of panitumumab in platinum-resistant advanced head and neck squamous cancer	automatically closed

## projects

<b>title</b>	<b>status</b>
An open-label, randomized, parallel group study of patients treated with Paclitaxel with standard dosing versus pharmacokinetic guided dose adjustment in patients with advanced NSCLC	completed
Entwicklung von Dienstleistungsmodellen der integrierten Onkologie und Palliative Care: Untersuchung von temporalen Aspekten, Involvierung von Onkologen, und Chemotherapie-Gebrauch	completed

## projects

title	status
Bevacizumab, pemetrexed and cisplatin, or erlotinib and bevacizumab for advanced non-squamous NSCLC stratified by EGFR mutation status. A multicenter phase II trial including biopsy at progression (BIO-PRO trial)	automatically closed
Preoperative chemotherapy and radiotherapy concomitant to Cetuximab in non-small cell lung cancer (NSCLC) patients with IIIB disease. A multicenter phase II trial	automatically closed
Carboplatin and Paclitaxel plus ASA404 as first line chemotherapy for extensive-stage small-cell lung cancer (ES-SCLC): A phase II trial	automatically closed
A Phase III, randomized, double-blind, placebo-controlled multi-center study of ASA404 in combination with paclitaxel and carboplatin as first-line treatment for locally advanced or metastatic (stage IIIb/IV) non-small cell lung cancer (NSCLC)	completed





## projects

<b>title</b>	<b>status</b>
Neoadjuvant chemotherapy and extrapleural pneumonectomy of malignant pleural mesothelioma (MPM) with or without hemithoracic radiotherapy. A randomized multicenter phase II trial	automatically closed



## projects

<b>title</b>	<b>status</b>
Preoperative chemoradiotherapy vs. chemotherapy alone in non-small cell lung cancer (NSCLC) patients with mediastinal lymph node metastases (stage IIIA, N2): A randomized prospective phase III trial	automatically closed